Madecassoside

Catalog No.S3843 Batch:S384301

Technical Data

Formula	C₄₈H₇₈O₂₀
Molecular Weight	975.12	CAS No.	34540-22-2
Solubility (25°C)*	In vitro	DMSO	100 mg/mL (102.55 mM)
		Water	100 mg/mL (102.55 mM)
		Ethanol	100 mg/mL (102.55 mM)
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description	Madecassoside (Asiaticoside A) is the main active triterpene constituent of Centella asiatica herbs, a traditional Chinese medicine for wound healing and scar management.
In vitro	Madecassoside (10, 30, 100 μmol/L) could reverse morphological changes, elevate cell viability, increase glutathione levels, and decrease lactate dehydrogenase andmalondialdehyde levels caused by H2O2 in a concentration-dependent manner. It attenuates apoptosis, preventing the activation of caspase-3 and the loss of mitochondria membrane potential, as well as the phosphorylation of p38 mitogen activated protein kinase (MAPK) in HUVECs. Hence, Madecassoside could protect HUVECs against lipid peroxidation and apoptosis caused by H2O2^[1].
In vivo	The pharmacokinetic study of madecassoside in rats indicates that the maximum plasma concentration is 303.75 ± 28.53 ng/mL after single oral administration (100 mg/kg). Madecassoside, administered orally for 20 days at doses of 6, 12, and 24 mg/kg, effectively facilitates burn wound healing in mice. It could reduce the burn wound area, leading to a better healing pattern with almost complete wound closure in mice^[1]. Madecassoside has potent anti-pulmonary fibrosis (PF) effects when administered p.o., despite having extremely low oral bioavailability. The potent anti-PF effects induced by p.o. madecassoside in mice are not mediated by its metabolites or itself after absorption into blood. i.p. madecassoside has no anti-PF effect. Madecassoside increases the activity of PPAR-γ, which subsequently increases HGF expression in colonic epithelial cells. HGF then enters into the circulation and lung tissue to exert an anti-PF effect^[2].

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines human umbilical vein endothelial cells (HUVECs) Concentrations 10, 30, 100 μmol/L Incubation Time 8 h Method HUVECs are harvested using 0.25% trypsin solution and inoculated in 96-well plates at a density of 1 × 10⁴ cells/well. Cells are treated with H2O2 (500 μmol/L) and/or a variety of concentrations of madecassoside (10, 30, 100 μmol/L). The culture plate is then placed in 5% (v/v) CO2 at 37◦C for 8 h. At the end of incubation, 20 μL of MTT (5 mg/mL) is added to each well and the cells are incubated for another 4 h at 37◦C with 5% CO2. The supernatants are then discarded, and 200 μL of DMSO is added to each well. The absorbance is read at 540 nm and cell viability is expressed as percentage of untreated cells.
Animal Study:^{^[2]}	Animal Models Female ICR mice, 6-8 weeks-old and weighing 22-26 g Dosages 40 mg/kg Administration p.o. or i.p.

Cell Assay:^{^[1]}

Cell lines
human umbilical vein endothelial cells (HUVECs)
Concentrations
10, 30, 100 μmol/L
Incubation Time
8 h
Method
HUVECs are harvested using 0.25% trypsin solution and inoculated in 96-well plates at a density of 1 × 10⁴ cells/well. Cells are treated with H2O2 (500 μmol/L) and/or a variety of concentrations of madecassoside (10, 30, 100 μmol/L). The culture plate is then placed in 5% (v/v) CO2 at 37◦C for 8 h. At the end of incubation, 20 μL of MTT (5 mg/mL) is added to each well and the cells are incubated for another 4 h at 37◦C with 5% CO2. The supernatants are then discarded, and 200 μL of DMSO is added to each well. The absorbance is read at 540 nm and cell viability is expressed as percentage of untreated cells.

Animal Study:^{^[2]}

Animal Models
Female ICR mice, 6-8 weeks-old and weighing 22-26 g
Dosages
40 mg/kg
Administration
p.o. or i.p.

References

Selleck's Madecassoside has been cited by 1 publication

Importance of telomere shortening in the pathogenesis of ulcerative colitis: A new treatment from the aspect of telomeres in intestinal epithelial cells [ J Crohns Colitis, 2021, jjab115]	PubMed: 34180971

Importance of telomere shortening in the pathogenesis of ulcerative colitis: A new treatment from the aspect of telomeres in intestinal epithelial cells [ J Crohns Colitis, 2021, jjab115]

PubMed: 34180971

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.